Post COVID-19 cerebral venous sinus thrombosis; a case report

Shwan A Ahmad; Fahmi H Kakamad; Hemin S Mohamad; Bestoon Kh Salih; Shvan H Mohammed; Berwn A Abdulla; Abdulwahid M Salih

doi:10.1016/j.amsu.2021.103031

Post COVID-19 cerebral venous sinus thrombosis; a case report

Ann Med Surg (Lond). 2021 Dec:72:103031. doi: 10.1016/j.amsu.2021.103031. Epub 2021 Nov 10.

Authors

Shwan A Ahmad¹, Fahmi H Kakamad^{1

2

3}, Hemin S Mohamad¹, Bestoon Kh Salih¹, Shvan H Mohammed², Berwn A Abdulla^{1

2}, Abdulwahid M Salih^{1

3}

Affiliations

¹ Smart Health Tower, Francios Mettarrand Street, Sulaimani, Kurdistan, Iraq.
² Kscien Organization, Hamdi Str, Azadi Mall, Sulaimani, Kurdistan, Iraq.
³ College of Medicine, University of Suleiman, Madam Mettarrand Street, Sulaimani, Kurdistan, Iraq.

Abstract

Introduction: Cerebral venous sinus thrombosis (CVST) in the setting of coronavirus disease 2019 (COVID-19) is an uncommon phenomenon with increasing incidence. This study aims to present a rare case of post COVID-19 CVST.

Case report: A 58-year-old female presented with headache, nausea, left sided weakness, and slurred speech. She recently recovered from COVID-19 who had severe presentations. On examination, mild left central facial palsy, high grade left sided hemiparesis (Grade 2/5), positive Babinski on left side, left side hypoesthesia, and inability to walk were observed. Laboratory and ultrasound findings were not significant, however magnetic resonance imaging (MRI) revealed CVST. The patient was prescribed Clexane 6000 IU twice daily, and after 14 days, it was changed to warfarin with an INR between 2 and 3. After 3 weeks of treatment, the patient was able to walk, and after 3 months her warfarin medication was discontinued.

Discussion: COVID-19 has been reported to be linked with CVST, however there is limited information about it. The exact figures regarding the affected groups and incidence rates are highly controversial. The diagnosis of CVST poses a challenge to physicians as their symptoms are highly unspecific, hence MRI is required for definitive diagnosis. Anticoagulant is commonly used in their treatment; however, the ideal anticoagulant of choice and the management duration are yet to be known.

Conclusion: Active or recently resolved COVID-19 can be considered as an independent risk factor for developing CVST and it rises the mortality rate of the disease.

Keywords: COVID-19; Cerebral venous sinus thrombosis; Neurologic complication; SARS-CoV-2.

Publication types

Case Reports